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laboratories, so the properties associated with STEC in S. 
sonnei isolates from patients remain undetected. S. sonnei 
with stx2a may have potential to cause severe disease, es-
pecially in children. This novel and remarkable virulence 
characteristic in Shigella spp. would affect diagnostics, 
infection control, and prevention.
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To the Editor: New World cutaneous leishmaniasis 
(CL), a zoonotic disease, is increasingly seen among trav-
elers returning from Latin American countries, particu-
larly from Bolivia, Belize, and French Guiana (1). The 
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Figure.	UPGMA	dendrogram	of	XbaI	restriction	patterns	of	2	Shigella sonnei	isolates	from	a	patient	from	Finland	who	became	ill	during	
a	visit	to	Morocco.	Genomic	comparison	of	the	2	isolates	was	performed	by	using	pulsed-field	gel	electrophoresis	according	to	the	
standard	protocol.	The	isolates	showed	96%	similarity,	and	a	3-fragment	difference	suggests	that	1	isolate	was	a	variant	of	the	other.	
Scale	bar	represents	%	similarity.	ial,	invasion-associated	locus;	ipaH,	invasion	plasmid	antigen	H;	invE,		invasion	gene	transcription	
regulator	invE;	stx2,	Shiga	toxin	2.
epidemiology of CL in the Americas is heterogeneous and 
has complex variations in transmission cycles, reservoir 
hosts, and sandfly vectors. Changing human activities that 
affect these factors may have resulted in the emergence of 
species with distinct pathogenic potentials and responses 
to therapy. In the Guianan ecoregion complex, leishmani-
asis is endemic, and 5 coexisting Leishmania parasite 
species are known to infect humans: L. guyanensis, L. 
braziliensis, L. amazonensis, L. naiffi, and L. lainsoni. 
Among these species, L. guyanensis accounts for ≈85% 
of CL cases (2).
We report an outbreak of 7 cases of L. braziliensis CL 
that occurred among 24 scientists who participated in a 
field mission at Limonade Creek in Saül, French Guiana, 
during October 10–25, 2013. Saül is an isolated village in 
the Amazonian rainforest (3°55′18′′N, 53°18′02′′W). 
Among the 7 patients, 6 were male; mean age was 32 
± 5 years. None of the patients were immunocompromised. 
The scientists stayed in Saül a mean of 17 (range 12–30) 
days. The mean time to symptom onset after they left Saül 
was 19 (range 0–50) days. The mean number of CL lesions 
was 2.3 (range 1–5). Lesions were localized mainly on low-
er limbs (11/14 lesions) but also appeared on upper limbs 
(2/14 lesions) and ears (1/14 lesions). CL was associated 
with nodular lymphangitis, adenitis, and superficial phlebi-
tis of the affected limb in 2, 3, and 1 patient, respectively. 
No patients had mucosal involvement, fever, or decline in 
general health. 
Diagnosis of CL was clinically suggested and con-
firmed by microscope examination of skin scrapings, 
which revealed typical amastigotes, by a positive Leish-
mania species–specific PCR result, or both. L. brazilien-
sis complex was diagnosed by using different molecular 
techniques, according to the laboratory, and then confirma-
tion of L. braziliensis species was conducted by the French 
National Reference Center for Leishmaniasis on the basis 
of a putative translation initiation factor a-subunit gene se-
quence (3). Leishmania strain genotyping was performed 
to explore the epidemiology of the implicated strains. Four 
single-copy genomic loci were amplified from 5 of 7 pa-
tient samples; 1 of the samples had a parasite DNA content 
that was too low to genotype, and 1 was not analyzed. The 
genetic analysis of the 4 concatenated sequences showed 
5 distinct and nonclustered genotypes (Figure). According 
to local protocols, patients were treated with 20 mg/kg of 
intramuscular meglumine antimoniate or with 18–38 mg/
kg of intravenous liposomal amphotericin B; at publication 
time, the patients were still being followed.
This outbreak of L. braziliensis CL in French Guiana 
raises the question of an overall increase in the incidence 
of this Leishmania species. Until now, outbreaks of L. bra-
ziliensis infection have been observed in Argentina, Brazil, 
Panama, and Venezuela but not Guiana (5–7). In French 
Guiana, changes in the epidemiology of CL have been 
observed since 2006; the emergence of L. braziliensis, L. 
amazonensis, and L. lainsoni infections represented 8.8%, 
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Figure.	Data	display	network	
showing	the	genetic	diversity	
of	32	Leishmania braziliensis 
(according	to	the	multilocus	
enzyme	electrophoresis–based	
taxonomy)	compared	with	5	
strains	from	clinical	samples	
(boldface)	obtained	from	visitors	
to the Amazonian forest region of 
French	Guiana.	The	strains	were	
compared	at	4	genomic	loci	(locus	
03.0980,	10.0560,	31.0280	and	
31.2610)	as	previously	described	
(3).	The	concatenated	nucleotide	
sequences	(2,610	bp)	were	
duplicated	to	avoid	information	
loss	due	to	heterozygous	
positions	(e.g.,	A	to	AA	or	Y	to	
CT).	Neighbor-Net	analysis	was	
performed	with	SplitsTree	version	
4.11.3	(http://splitstree.org/)	by	
using	p-distances	and	equal	edge	
lengths	(4).	Two	L. guyanensis 
strains	were	used	as	an	outgroup.	
The	inset	represents	the	genetic	
distance	between	L.	guyanensis	
and	L.	braziliensis.	Scale	bar	
indicates	evolutionary	distance.
2.6%, and 1.4%, respectively, of the diagnosed CL cases 
(8). This trend could be due either to an increase of L. bra-
ziliensis prevalence in the forests of Guiana or to a greater 
presence of humans (e.g., military personnel, scientists, 
and tourists) in deep forest areas with hot spots of transmis-
sion. Favorable environmental conditions in a well-delim-
ited zoonotic microfocus hot spot might have contributed 
to this high rate of transmission. However the relative ge-
netic diversity of strains we observed among the 5 analyzed 
patients was unexpected, given the relatively small spatial 
and temporal scale of the transmission area, and indicates 
that the reservoirs in this restricted area were infested by 
distinct genotypes. Development of a peridomestic cycle, 
perhaps with specific reservoirs (pets) and vectors, cannot 
be excluded in the Saül area.
This case series suggests that caution should be taken 
in the diagnosis and treatment of CL in patients returning 
from the Amazonian rainforest, and a species-specific ap-
proach based on molecular identification should be pro-
posed to provide appropriate medical management (9). In-
deed, although L. braziliensis parasites cause <10% of CL 
acquired in French Guiana, this species is noteworthy for 
its involvement of the mucous membranes of the lips, nose, 
soft palate, or larynx. Also, L. braziliensis parasites usu-
ally fail to respond to pentamidine isethionate, the first-line 
treatment of L. guyanensis CL in French Guiana; instead, 
treatment of L. braziliensis infection relies on parenteral 
meglumine antimoniate or liposomal amphotericin B (1).
In summary, the geographic extension of and numeric 
increase in L. braziliensis cases in the Guiana ecoregion 
complex, as observed in the rest of South America, are wor-
risome, and continuous epidemiologic surveillance is need-
ed. Infection with L. braziliensis, which is emerging and 
has potential to disseminate, must be considered in cases of 
CL acquired in this region. These issues have key implica-
tions for leishmaniasis treatment, which should be directed 
to the identified species (10).
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To the Editor: Shigellosis is an uncommon infection 
in many industrialized countries, and many cases are linked 
to travel to Shigella spp.–endemic countries. The epide-
miology of Shigella infections in developing countries is 
changing. S. sonnei seems to be replacing the more antigen-
ically diverse S. flexneri in regions undergoing economic 
development and improvements in water quality (1).
In 2012, a total of 29 cases of shigellosis were reported 
in Ireland through the Computerized Infectious Disease 
Reporting system (crude incidence rate 0.63 cases/100,000 
population). Isolates from 20 (69%) of those 29 cases were 
submitted to the National Reference Laboratory in Galway, 
Ireland, for additional typing. In 2013, a total of 43 isolates 
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